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Direct lineage conversion could provide a rich source of somatic cell types for translational medicine, but
concerns over the use of transgenic reprogramming factors have limited its potential. In this issue of Cell
Stem Cell, Li et al. (2015) and Hu et al. (2015) identify small-molecule cocktails that can convert fibroblasts
into functional neurons without exogenous genetic factors.Not long ago, Yamanaka and colleagues
took a giant leap for translational medi-
cine by demonstrating that a simple com-
bination of four genes can reprogram
somatic cells (Takahashi and Yamanaka,
2006). Several groups later adapted this
approach and showed that it is possible
to directly generate cells of many different
tissue types using a similar approach,
from neurons (Son et al., 2011; Vierbu-
chen et al., 2010) to cardiomyocytes
(Ieda et al., 2010) to hepatocytes (Du
et al., 2014). In the context of cell trans-
plantation, direct lineage conversion has
substantial appeal because cells do not
transit through the tumorigenic pluripo-
tent state. However, the need for using
transgenic reprogramming factors in this
approach still presents major technical
and safety concerns (Xu et al., 2015).
In this issue of Cell Stem Cell, both Li
et al. (2015) and Hu et al. (2015) take a
big step in alleviating these concerns by
demonstrating that small molecules alone
are capable of converting fibroblasts into
neurons.
To identify a neuron-inducing cocktail,
Hu and colleagues began with a cocktail
of VPA, CHIR99021, and Repsox that
they had previously shown to be capable
of converting fibroblasts into neural pro-
genitor cells (Cheng et al., 2015), and
they supplemented this with chemicals
known to promote the differentiation of
neural progenitors into neurons (Forsko-
lin, SP600125, GO6983, and Y-27632)
(Figure 1). Notably, they showed that the
final cocktail converted multiple adult hu-
man fibroblast lines into functional neu-
rons at a decent efficiency (one to three
neurons for every ten starting fibroblasts).Li and colleagues took a different
approach and leveraged knowledge of a
defined set of transcription factors that
can convert fibroblasts into neurons
(Vierbuchen et al., 2010). They initially
screened for chemicals that promote
reprogramming in the presence of Ascl1.
Excitingly, they found that simultaneous
administration of four of the chemicals
identified as individual promoters of
Ascl1-based reprogramming converted
mouse embryonic fibroblasts (MEFs)
into immature neurons without Ascl1
overexpression. After further screening,
an optimal combination of Forskolin,
ISX9, CHIR99021, and I-BET151 (FICB)
was determined to generate functional
chemically induced neurons (CiNs) from
fibroblasts at an extremely high efficiency
(nine neurons for every ten starting
fibroblasts).
CiNs produced by both cocktails
possess several functional hallmarks
of neurons, including extensive neurite
outgrowth and branching, voltage-
dependent ion channels, the ability to
fire action potentials and respond to
glutamate and GABA, and the capacity
to form afferent synapses with primary
neurons. Hu et al. used calcium imaging
to infer that a large portion (similar to
stem cell-derived neuron cultures) of their
CiNs were active. RNA-seq analysis by
both groups reinforced these results,
showing that CiNs are indeed quite similar
to stem cell-derived neurons and tran-
scription-factor-induced neurons, while
diverging significantly from fibroblasts.
In addition, single-cell transcriptional
analysis by both groups showed that the
vast majority of CiNs express a neuronalCell Stem Cell 1transcriptional profile and have silenced
the fibroblast network. Interestingly,
both groups inferred that most of their
CiNs are excitatory, glutamatergic neu-
rons due to strong vGlut expression,
while a small fraction of cells express
GABAergic neuron markers. No substan-
tial populations of cholinergic or dopami-
nergic neurons appeared to form.
MEF cultures contain a mixture of
embryo-derived cell types, so there was
a possibility that the chemical cocktail
identified by Li et al. was acting predomi-
nantly on neural progenitor cells that
lingered in the cultures as opposed to
fibroblasts. To distinguish between these
possibilities, they performed a lineage-
tracing experiment using the fibroblast
reporter Fsp1-cre MEFs. This experiment
confirmed that their small-molecule
mixture is capable of efficiently converting
fibroblasts into neurons. In addition, the
study by Hu et al. provides compelling
evidence that mature, adult fibroblasts
are also amenable to chemical neuronal
conversion.
How do these chemical combinations
induce neurogenesis? Both Li et al. and
Hu et al. found little evidence for a transi-
tion through a neural progenitor state. Cell
division stopped within 3 days of either
chemical treatment and Hu et al. were
unable to detect the induction of canoni-
cal neural progenitor genes, suggesting
that conversion occurs directly.
Both cocktails clearly required synergy
between the small molecules to induce
full conversion, and the fact that both
sets included CHIR99021 and Forskolin
suggest that glycogen synthase kinase-3
inhibition and cyclic AMP stimulation7, August 6, 2015 ª2015 Elsevier Inc. 127
Figure 1. Summary of the Chemical Conversion of Fibroblasts into Neurons
Two different small-molecule cocktails convert fibroblasts into vGlut1+ or GABA+ neurons, neither one
transiting cells through a neural progenitor state. Certain chemicals destabilize the fibroblast state while
others seem to induce neurogenesis. (Image credit: Kristen Chen.)
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Li et al. found that different small mole-
cules acted on different aspects of the
conversion process. The bromodomain
inhibitor I-BET151 destabilized the start-
ing fibroblast state by reducing the
expression of key fibroblast transcription
factors. This function is consistent with
the known role of bromodomain proteins
in coupling histone acetylation to tran-
scription. In contrast, ISX9 treatment
activated the expression of neurogenic
transcription factors. Importantly, both
studies noted a surge in electrophysio-
logical and synaptic maturity when CiNs
were co-cultured with primary glia, indi-
cating that glial-derived factors also
contribute to the reprogramming process.
The demonstration that small mole-
cules alone can convert fibroblasts into
neurons raises tantalizing possibilities128 Cell Stem Cell 17, August 6, 2015 ª2015and important questions that have direct
implications for the translational utility of
these cells. Can these cells engraft and
function in vivo? Will they form func-
tional, efferent synapses as well as the
afferent synapses demonstrated in the
papers?
Mammals have an incredible diversity
of neuronal subtypes, each having a
unique set of molecular properties that
combine to enable the complex functions
of the brain, sensory, and motor systems.
The dysfunction of specific neuronal
subtypes also causes the stereotyped
symptoms associated with neurological
disease. Is it possible to use chemicals
to induce a specific neuronal subtype?
How closely would these neurons
mimic their primary counterparts, and
how would this affect their ability to
engraft upon transplantation or recapitu-Elsevier Inc.late disease in vitro? Hu and colleagues’
finding that neurons generated from
Alzheimer’s disease patient fibroblasts
had an increased Ab42/Ab40 ratio remi-
niscent of Alzheimer’s disease brains is
highly promising, but further experimen-
tation must be done to identify disease
processes in the CiN cultures.
Could this approach work for other,
more easily obtainable cell sources such
as peripheral blood mononuclear cells?
For regenerative medicine, would it be
possible to generate new neurons in situ
by injecting a chemical cocktail into the
brain? Do the CiNs retain any properties
of the starting cells such as their age or
specific chromatin and gene expression
signatures?
Together, these groups have taken a
major step in showing that small mole-
cules alone can convert fibroblasts into
neurons. While there remain many impor-
tant unanswered questions about sub-
type specification and translational utility,
these studies provide a key starting point
for these efforts. They also show that
small molecules can drastically alter the
plasticity and fate of somatic cells. Here,
Li et al. used a step-wise procedure in
which they first screened for molecules
to enhance transcription-factor-mediated
conversion and later determined if a
combination of the resulting hits could
replace the transcription factors alto-
gether. The same group previously
employed this approach to identify a
chemical cocktail capable of reprogram-
ming fibroblasts into iPSCs (Hou et al.,
2013), suggesting that this strategy could
serve as a blueprint for developing chem-
ical combinations to reprogram cells into
other lineages.
Interestingly, VPA and Repsox from the
Hu et al. protocol were previously identi-
fied in iPSC reprogramming screens
(Ichida et al., 2009) and are part of the
all-chemical iPSC cocktail (Hou et al.,
2013), as are CHIR99021 and Forskolin,
the two molecules common to both
neuron-inducing cocktails. Although the
scientific basis for this convergence re-
mains to be determined, it may suggest
that fibroblasts enter a highly plastic,
but post-mitotic, cell state before
transitioning into neurons. Slight modifi-
cations of the chemical recipe may yield
additional lineages. Understanding, opti-
mizing, and harnessing the small-mole-
cule reprogramming approach will lead
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modeling and regenerative medicine in
the future.REFERENCES
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Therapeutic targeting of pre-leukemic stem cells (pre-LSCs) may be a viable strategy to eradicate residual
disease and prevent leukemia relapse. Now in Cell Stem Cell, Cai et al. (2015) show that loss-of-function
mutations in RUNX1 reduce ribosome biogenesis and provide pre-LSCs a selective advantage over normal
hematopoietic cells through increased stress resistance.The myelodysplastic syndromes (MDSs)
are a heterogeneous group of clonal
bone marrow malignancies characterized
by ineffective hematopoiesis, the pres-
ence of dysplastic cells in the bone
marrow, and peripheral blood cytopenias.
MDS occurs more frequently in older
males and in individuals with prior expo-
sure to cytotoxic therapy (Garcia-Manero,
2012), and individuals with MDS have an
increased risk of developing acute
myeloid leukemia (AML) (Heaney and
Golde, 1999). Recent experimental evi-
dence suggests that MDS arises from
a series of transforming events that
accumulate to generate pre-leukemic
stem cells (pre-LSCs), the precursors of
fully transformed LSCs (Pandolfi et al.,
2013). Transformational genetic and
epigenetic changes are believed to selec-
tively expand pre-LSCs in the bonemarrow, which then out-compete normal
hematopoietic stem and progenitor cells
(HSPCs). Genome-wide studies have
recently identified a number of genetic
lesions that are implicated in this process
and the development and/or progression
of MDS. These lesions have so far been
found in splicing factor genes (e.g.,
SF3B1 and SRSF2) as well as genes
involved in regulating DNA methylation
(e.g., TET2, IDH, and DNMT3A), histone
modification (e.g., ASXL1 and EZH2),
and several signal transduction and
transcription factors (e.g., RUNX1, p53,
EVI1, JAK2, and FLT3). In this issue
of Cell Stem Cell, Cai et al. (2015)
show that mutations in the transcription
factor RUNX1 reduce ribosomal biogen-
esis and provide a competitive advan-
tage to pre-LSCs by enhancing stress
resistance.Almost half of MDS patients present
with recurring karyotypic abnormalities
affecting chromosomes 5, 7, 8, and 20,
many of which impact the ribosome.
Hemizygous loss of the ribosomal
protein gene Rps14 contributes to the
development of anemia in 5q syndrome
(Ebert et al., 2008). Nucleophosmin,
which is located on chromosome
5q35.1, has been implicated in MDS
pathogenesis and is also critical for ribo-
some function (Grisendi et al., 2006;
Reschke et al., 2013). Other genetic
abnormalities cause impaired ribosome
biogenesis (Ribi) and function—a collec-
tion of disorders known as ribosomopa-
thies. Researchers have also found an
association between ribosomal stress
and activation of p53. In their current
study, Cai et al. have focused on
Runx1, a DNA binding transcription7, August 6, 2015 ª2015 Elsevier Inc. 129
